Targeted Strategies for Today's Evolving Markets

MissionIR Blog Featured Company: Pluristem Therapeutics Inc. (PSTI)

In less than a month’s time, Jonathan Lebed’s recommendation to buy PSTI on April 5th at $2.05 has translated into a 148% profit. That is an incredible value, and one of the reasons for this increase – and potential future increases – lies in the cutting edge technology that Pluristem possesses. Pluristem Therapeutics engages in the research and development of mesenchymal and stem cell production technology, and the commercialization of cell therapy products. Their cell therapy products are used for the treatment of a variety of severe degenerative, ischemic and autoimmune disorders where current therapies are unavailable or inadequate.

This field is still somewhat controversial, but is creating some of the best cures for diseases that were previously thought to be untreatable. Pluristem has three products currently on the market, PLX-PAD, PLX-I and PLX-STROKE, which have proven benefits in the medical community. PLX-PAD is intended to treat patients suffering from the critical stage of peripheral artery disease (PAD), manifesting as limb ischemia. It has been proven to increase blood flow to lower extremities that surgery and traditional medicine cannot match. PLX-I is intended to resolve the global shortfall of matched hematopoietic stem cells (HSCs) for bone marrow transplantation. Over 60% of leukemia patients in need of transplant are unable to find a suitable match, but – if successfully combined with umbilical cord blood – this technology will create an alternative to the transplant with no matching required.

Pluristem Therapeutics announced on April 23 that it was chosen to present at the First Annual Israeli Presidential Conference termed “Facing Tomorrow”, to be held on May 13-15, 2008 in Jerusalem. The conference will focus on Jewish and Israeli contributions to humanity, and will showcase 60 inventions and innovations developed by Israeli scientists, researchers and inventors that have the potential to revolutionize the future for Israel as well as the world. In addition to hundreds of leading scientists, researchers and inventors, the most notable guests attending the conference will be President George W. Bush, Former British Prime Minister Tony Blair, Former President of the USSR Mikhail Gorbachev, Former U.S. Secretary of State Dr. Henry Kissinger, New York Times columnist Thomas L. Friedman, and Chairman and CEO of News Corporation, Rupert Murdoch.

Pluristem’s President and CEO, Zami Aberman, stated, “Pluristem is pleased to be invited to this high level international conference to present its business and products in development to world-renowned business leaders, technology thought leaders and entrepreneurs.” “It will be the first opportunity for the company to show their technology to outsiders of the medical community. Lebed and others believe that this stock could take off in the weeks following this world famous conference.

Let us hear your thoughts below:

This entry was posted in Small Cap News. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *